Coming May 2025
Get Early Access
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
40 employees
Imbed Biosciences: A Madison-based medical device company innovating in wound care and surgical implants.
HQ
Founded
2010
Imbed Biosciences, founded in Madison, Wisconsin, is a medical device company dedicated to advancing wound care and surgical implants. The company's core mission is to develop and commercialize innovative technologies that embed bioactive molecules into wound dressings and surgical implants, aiming to improve healing outcomes and reduce infection rates. Imbed Biosciences offers products such as Microlyte® Matrix, Surgaflex™, and PelashieldAM™, targeting healthcare providers and patients in need of advanced wound care solutions.
Notable affiliated individuals include experts in biomedical engineering and clinical medicine who contribute to the company's innovative edge. Imbed Biosciences has garnered attention from investors focused on healthcare innovation. Key achievements include the successful commercialization of their flagship product, Microlyte® Matrix, which has been adopted by numerous healthcare facilities. The company's impact lies in its ability to enhance patient care through cutting-edge technology, positioning itself as a leader in the medical device industry.
Operating Status
Active
Ownership Type(s)
Venture Capital
Main Product(s)
Medical Devices
Technology
Biotech
Tags
Healthtech
Model Types
Hardware, Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise, Government
Geographic Exposure
United States
When was Imbed Biosciences founded?
Imbed Biosciences was founded in 2010.
Where is Imbed Biosciences's headquarters located?
Imbed Biosciences's headquarters is located in Fitchburg, US.
When was Imbed Biosciences's last funding round?
Imbed Biosciences's most recent funding round was for $10M (USD) in January 2024.
How many employees does Imbed Biosciences have?
Imbed Biosciences has 40 employees as of Feb 5, 2024.
How much has Imbed Biosciences raised to-date?
As of July 05, 2023, Imbed Biosciences has raised a total of $22.9M (USD) since Jan 8, 2024.
Add Comparison
Total Raised to Date
$22.9M
USD
Last Update Jan 8, 2024
Last Deal Details
$10M
USD
Jan 8, 2024
Convertible Note
Current Employees
40
Last updated: Feb 5, 2024
No location information available for this company.
Locations
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts